Palisade Bio Announces Inducement Grants Under Nasdaq Listin...| MENAFN.COM

Sunday, 02 October 2022 10:32 GMT

Palisade Bio Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)


(MENAFN- GlobeNewsWire - Nasdaq)

Carlsbad, CA, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc.   (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that it had made equity grants to two new employees under its 2021 Inducement Plan.

On August 29, 2022, the Company's Compensation Committee granted options to two new non-executive employees covering an aggregate of 93,000 shares of the Company's common stock as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

The options have an exercise price equal to the closing price of the Company's common stock on the date of grant. The options granted to each employee vest in equal proportions each quarter for three years. In all cases, the options are contingent on each employee's continued service with the Company at the applicable vesting date.

About Palisade Bio

Palisade Bio is a late-stage biopharmaceutical company focused on developing therapeutics that protect the integrity of the intestinal barrier. The Company utilizes over three decades of research and established science that links the role of intestinal barrier biology and human disease to develop novel therapeutics that target and improve the integrity of the intestinal barrier.

The Company's lead program, LB1148, is a broad-spectrum serine protease inhibitor which acts to neutralize digestive enzymes, potentially reducing intestinal damage. In multiple clinical studies, LB1148 has demonstrated positive results in accelerating the time to return of postoperative bowel function, and the Company recently presented analysis that LB1148 reduced the incidence and severity of post-surgical abdominal adhesions. LB1148 is currently being evaluated in a Phase 3 clinical study for accelerating the return of postoperative bowel function and in a Phase 2 study for the prevention of post-surgical abdominal adhesions.

The Company believes that addressing the disruption of the intestinal barrier has the potential to fundamentally change the way diseases are treated and to establish new standards of patient care. For more information, please go to .

Forward Looking Statements
This communication contains“forward-looking” statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include statements regarding Palisade's intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: the potential to fundamentally change the way diseases are treated, the completion of enrollment for the Phase 3 study, the potential for the statistically significant Phase 3 data to allow for NDA approval, and the potential for LB1148 to establish the standard of care, if approved. Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements are based upon Palisade's current expectations. Forward-looking statements involve risks and uncertainties. Palisade's actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, without limitation, the company's ability to advance its clinical programs, the uncertain and time-consuming regulatory approval process; the company's ability to achieve additional financing to fund clinical development and the company's ability to comply with the continued listing requirements for Nasdaq. Additional risks and uncertainties can be found in Palisade Bio's Quarterly Report on Form 10-Q for the quarter ended June 30, 2022. Palisade expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in Palisade's expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based.

Investor Relations Contact
JTC Team, LLC
Jenene Thomas
833-475-8247

Source: Palisade Bio




Tags Palisade Bio Inc. PALI biopharmaceutical clinical chronic gastrointestinal therapeutics human disease intestinal barrier acute

MENAFN23092022004107003653ID1104916466


Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.